Merck announces Phase 3 trial initiations for 4 Investigational Candidates from hematology and oncology pipeline

Comprehensive clinical development programs being initiated for each investigational candidate

Dr. Reddy's acquires MenoLabs

Alkem completes sale of St. Louis manufacturing facility for US$ 7.96 million

The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year

USFDA grants priority review for Patritumab Deruxtecan in US for certain patients with EGFR-mutated non-small cell lung cancer

If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients

UPM Biomedicals enters into distribution agreement with Brinter for GrowInk bioinks

The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries

FDA grants priority review to Merck’s new biologics license application for V116

V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults

Dr. Reddy's becomes first Indian pharma company to debut on the DJSI

Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis

Lupin Diagnostics opens new laboratory in Chennai

The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies

Merck and Moderna initiate Phase 3 study evaluating V940 (mRNA-4157) in combination with Keytruda for treatment of non-small cell lung cancer

The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)

Dr. Reddy's inks pact with Coya Therapeutics for development of sclerosis drug

Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya